KalVista Pharmaceuticals Lands $33,000,000 Series B Funding
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=90074949-ad06-4131-85c7-f6eeb1814383 - Date
7/23/2015 - Company Name
KalVista Pharmaceuticals - Mailing Address
75 Arlington Street Boston, MA 02116 USA - Company Description
KalVista is a research-led pharmaceutical company focused on the discovery, development and commercialization of small molecule serine protease inhibitors as new treatments for diseases with significant unmet need. - Website
http://www.kalvista.com - Transaction Type
Venture Equity - Transaction Amount
$33,000,000 - Transaction Round
Series B - Proceeds Purposes
KalVista will use the funds to advance its proprietary portfolio of plasma kallikrein inhibitors for treating diabetic macular edema (DME) and hereditary angioedema (HAE). - M&A Terms
- Venture Investor
RA Capital - Venture Investor
Longwood Fund - Venture Investor
Venrock - Venture Investor
Novo Ventures - Venture Investor
SV Life Sciences
